57573-59-8

Basic information

• Product Name: 6-BROMO-3-METHYLQUINAZOLIN-4(3H)-ONE
• Synonyms: 6-BroMo-3-Methyl-3H-quinazolin-4-one;6-BROMO-3-METHYL-4-QUINAZOLINONE;6-Bromo-3-methylquinazolin-4(3H)-one
• CAS NO: 57573-59-8
• Molecular Formula: C₉H₇BrN₂O
• Molecular Weight: 239.07
• EINECS: 200-589-5
• Mol File: 57573-59-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 364.2°C at 760 mmHg
• Flash Point: 174°C
• Appearance: /
• Density: 1.65g/cm³
• Vapor Pressure: 1.71E-05mmHg at 25°C
• Refractive Index: 1.67
• Storage Temp.: 2-8°C
• PKA: 0.90±0.70(Predicted)
• CAS DataBase Reference: 6-BROMO-3-METHYLQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3-METHYLQUINAZOLIN-4(3H)-ONE(57573-59-8)
• EPA Substance Registry System: 6-BROMO-3-METHYLQUINAZOLIN-4(3H)-ONE(57573-59-8)

Safety Data

• Hazardous Substances Data: 57573-59-8(Hazardous Substances Data)

Usage

General Description

6-Bromo-3-methylquinazolin-4(3H)-one is a chemical compound that belongs to the quinazolinone family. It is a derivative of quinazolinone and contains a bromine atom at the 6-position and a methyl group at the 3-position of the quinazolin-4-one core. 6-Bromo-3-methylquinazolin-4(3H)-one has potential biological and pharmacological activities and has been studied for its anti-tumor and anti-inflammatory properties. It has also been used as a building block in the synthesis of various pharmaceutical agents and bioactive molecules. The structure and properties of 6-Bromo-3-methylquinazolin-4(3H)-one make it a valuable target for medicinal chemistry research and drug development.

InChI:InChI=1/C9H7BrN2O/c1-12-5-11-8-3-2-6(10)4-7(8)9(12)13/h2-5H,1H3

Upstream product

• 123-39-7 N-Methylformamide 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 32084-59-6 6-bromo-4-hydroxyquinazoline 
• 74-88-4 methyl iodide 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 6214-20-6 methyl 4-nitrobenzenesulfonate 
• 91-56-5 indole-2,3-dione 
• 4692-98-2 5-bromoisatoic anhydride 
• 74-89-5 methylamine 
• 134-20-3 2-carbomethoxyaniline 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 

Downstream Products

• 878745-39-2 tert-butyl 4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenylcarbamate 
• 951627-58-0 4-methyl-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]benzoic acid 
• 951627-57-9 4-methyl-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]-N-[2-(trifluoromethyl)pyridin-4-yl]benzamide 
• 1209485-71-1 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4(3H)-one 
• 1396310-22-7 N-(2,4-difluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396311-66-2 N-(2,4-difluoro-3-(methyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)-N-(4-methoxybenzyl)propane-1-sulfonamide 
• 1396310-24-9 N-(2,4-difluoro-3-(methyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide 
• 1396310-76-1 N-(4-chloro-2-fluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)dimethylsulfamide 
• 1396310-77-2 N-(4-chloro-2-fluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)pyrrolidine-1-sulfonamide 
• 1396311-65-1 N-(2,4-difluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)-N-(4-methoxybenzyl)propane-1-sulfonamide 
• 1396311-01-5 N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-25-0 N-(2-chloro-4-fluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-72-7 N-(4-chloro-2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-74-9 N-(2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 

Relevant articles and documents

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

Synthesis and biological evaluation of some amino- and sulfanyl-3H-quinazolin-4-one derivatives as potential anticancer agents

A series of 6-substituted quinazolinone derivatives were prepared by the reaction of 6-bromoquinazolinones with aryl or alkyl amines and thiols, in the presence of a Pd(OAc)2/Xantphos system, under Buchwald-Hartwig-type reaction conditions. The 6-bromoquinazolinones were obtained in the three-components reaction of 5-bromoisatoic anhydride, triethyl orthoformate and an appropriate amine. Biological screening of the potential cytotoxicity of synthesized compounds on HT29 and HCT116 cell lines, as well as on the lymphocytes, showed that some derivatives of quinazolinone have significant anticancer activities. The detailed synthesis, spectroscopic data, and biological assays were reported.

BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.